To include your compound in the COVID-19 Resource Center, submit it here.

Cancer Research, Parker Institute partner to test I-O combos for pancreatic cancer

CRI and the Parker Institute for Cancer Immunotherapy partnered with Bristol-Myers Squibb Co. (NYSE:BMY) and Apexigen Inc. (San Carlos, Calif.) to evaluate combinations of immunotherapies with chemotherapy to treat pancreatic cancer.

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE